CHNA China Biopharma ETF

No holdings information is available in our database.

CHNA China Biopharma ETF

Seeks to track, before fees and expenses, the Loncar China BioPharma Index, an index of 28 securities that have a strategic focus on advancing China’s biopharma industry. With a focus on innovators, the index contains globally listed pharmaceutical companies, biotech companies, drug manufacturers, diagnostics companies, wholesalers, distributors and service providers that have a strategic role in growing China’s drug industry. The Index includes stocks traded in the U.S. and Hong Kong but not in China. Stocks must have a minimum market cap of $200 million. All companies are initially given equal weight and then weighting factors are applied based on market capitalization categories. Companies with a market capitalization greater than $10 billion are given a weighting factor of 1.4, companies with a market capitalization between $1 billion and $10 billion are given a weighting factor of 1.0, and companies with a market capitalization between $200 million and $1 billion are given a weighting factor of 0.7.

As of 05/20/2022     IEX book   CBOE book

ETF Information
Sponsor:     Loncar Funds
Category1:  Global Equity
Category2:  Single country
Category3:  Health care
Morningstar category:  China Region
Country:      China
Leverage factor:  1.00
Inception date:  08/14/2018
Index tracking method: Passive replication
Current yield:  17.12%
Historical average yield:  3.05%
Market cap:  $5,391,000
Average volume:  5,431
Fees:     0.7900%

Index Information
Loncar China BioPharma Index
Index symbol:  LCHINA
Provider:   Loncar Investments
Index weighting:   Other
Index inception date:  02/13/2018
Backtesting data exists:   No
Number of holdings:  29  (as of 11/20/2018)
Rebalanced:  Semi-annually
Reconstituted:  Semi-annually

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy